Drug intelligence / Profile preview

PTX-205

Development stage: Preclinical
Lead developer: Providence Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PTX-205 is an mRNA-based vaccine candidate being developed by Providence Therapeutics for the prevention of infection caused by highly pathogenic influenza viruses. The vaccine utilizes messenger RNA technology to deliver genetic sequences encoding specific influenza virus antigens into host cells. Once translated, these antigens trigger a robust and targeted immune response, including the production of neutralizing antibodies and the activation of T cells, to establish protective antiviral immunity. PTX-205 is currently in the pre-IND (Investigational New Drug) stage of development, representing a key component of Providence's infectious disease portfolio focused on high-risk viral pathogens.

Beyond the preview

Go deeper on PTX-205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTX-205.

Explore the full profile